J. van Dalem

First name

J.

Last name

van Dalem

van Dalem, J., Werkman, C., van den Bergh, J. P., Rossi, B., Viggers, R., Eastell, R., et al. (2022). "Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort study". Diabetes Res Clin Pract, 109993. http://doi.org/10.1016/j.diabres.2022.109993

View

Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., et al. (2016). Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12605

View

van Dalem, J., Brouwers, M. C., Stehouwer, C. D., Krings, A., Leufkens, H. G., Driessen, J. H., et al. (2016). Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. Bmj. http://doi.org/10.1136/bmj.i3625

View

van Dalem, J., Brouwers, M., Stehouwer, C. D. A., Krings, A., Klungel, O. H., Driessen, J. H. M., et al. (2018). Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.13168

View

van Dalem, J., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. (2021). Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology. http://doi.org/10.1002/hep.32012

View

van Dalem, J., Brouwers, C., Burden, A. M., C, D. A. S., Klungel, O. H., de Vries, F., & Driessen, H. (2021). "Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: a retrospective cohort study". Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2021.108828

View